Home Cart Sign in  
Chemical Structure| 52286-59-6 Chemical Structure| 52286-59-6

Structure of Ginsenoside Re
CAS No.: 52286-59-6

Chemical Structure| 52286-59-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ginsenoside Re is a panaxatriol saponin that has diverse in vitro and in vivo effects, including vasorelaxant, antioxidant, antihyperlipidemic, and angiogenic actions.

Synonyms: Panaxoside Re; Ginsenoside B2; NSC 308877

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ginsenoside Re

CAS No. :52286-59-6
Formula : C48H82O18
M.W : 947.15
SMILES Code : C[C@@]12[C@@]([H])([C@](C)([C@]3([C@H](C2)O[C@@H]([C@@H]4O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)O)O)O)O[C@@H]([C@H]([C@@H]4O)O)CO)[H])CC[C@@H](C3(C)C)O)C[C@H]([C@]6([C@]1(CC[C@@]6([C@@](C)(O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)CO)CC/C=C(C)\C)[H])C)[H])O
Synonyms :
Panaxoside Re; Ginsenoside B2; NSC 308877
MDL No. :MFCD00133369
InChI Key :PWAOOJDMFUQOKB-WCZZMFLVSA-N
Pubchem ID :441921

Safety of Ginsenoside Re

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ginsenoside Re

MAPK
pyroptosis
TLR

Isoform Comparison

Biological Activity

Target
  • JNK

In Vitro:

Cell Line
Concentration Treated Time Description References
SH-SY5Y cells 25 µM 24 hours To evaluate the protective effect of ginsenoside Re against Aβ25-35-induced cytotoxicity and apoptosis, results showed ginsenoside Re significantly increased cell viability and reduced apoptosis. Molecules. 2019 Jul 24;24(15):2687
SH-SY5Y cells 10–100 µM 9 h pretreatment followed by 24 h exposure to 6-OHDA To evaluate the protective effect of ginsenoside Re against 6-OHDA-induced cellular damage. Results showed that ginsenoside Re significantly inhibited 6-OHDA-triggered cellular damage, reduced LDH release, and improved cell viability. Molecules. 2020 Jan 2;25(1):188
Mouse bone marrow-derived macrophages (BMMs) 0-10 μM 3 days To investigate the effect of Ginsenoside Re on RANKL-induced osteoclast differentiation, results showed that Ginsenoside Re inhibited osteoclast differentiation in a dose-dependent manner. Mol Cells. 2016 Dec;39(12):855-861
Mouse osteoblast precursor MC3T3-E1 cells 50 μM 21 days To evaluate the effect of ginsenoside Re on mineralization, results showed significant increase in calcium deposition at 50 μM. Molecules. 2016 Dec 29;22(1):42
Mouse osteoblast precursor MC3T3-E1 cells 50, 100 μM 14 days To evaluate the effect of ginsenoside Re on alkaline phosphatase (ALP) activity, results showed significant promotion of ALP activity at 50-100 μM. Molecules. 2016 Dec 29;22(1):42
Mouse osteoblast precursor MC3T3-E1 cells 5, 10, 25, 50, 100 μM 24 hours To evaluate the effect of ginsenoside Re on cell viability in MC3T3-E1 cells, results showed no cytotoxicity at 100 μM. Molecules. 2016 Dec 29;22(1):42
Cardiac fibroblasts 50 μmol/L, 100 μmol/L, 200 μmol/L 24 hours To investigate the effect of Ginsenoside Re on AngII-induced fibrosis in cardiac fibroblasts. Results showed that Ginsenoside Re could inhibit the expression of collagen I, collagen III, and α-SMA, alleviating fibrosis. J Ginseng Res. 2023 Mar;47(2):218-227
human dermal papilla cells (hDPCs) 3 μM 6 hours To investigate the effect of ginsenoside Re on autophagy, results showed that ginsenoside Re increased LC3-II conversion and Beclin 1 expression, promoting autophagy. J Ginseng Res. 2023 May;47(3):440-447
mouse small intestine interstitial cells of Cajal 20-40 μM To investigate the effects of Ginsenoside Re on the pacemaker activity of interstitial cells of Cajal, results showed that Ginsenoside Re decreased the amplitude and frequency of pacemaker activity in a concentration-dependent manner. J Ginseng Res. 2015 Oct;39(4):314-21
HT22 hippocampal neuronal cells 2.5, 5.5 or 7.5 µg/ml 1 hour Ginsenoside Re protected hippocampal neuronal cells by reducing inflammatory and neurotoxic factors released from microglial cells. Mol Med Rep. 2021 Oct;24(4):698
Mouse primary microglia 2.5, 5.5 or 7.5 µg/ml 1 hour Ginsenoside Re inhibited NO production and the expression of iNOS and COX-2. Mol Med Rep. 2021 Oct;24(4):698
BV2 microglial cells 2.5, 5.5 or 7.5 µg/ml 1 hour Ginsenoside Re significantly inhibited LPS-induced production of IL-6, TNF-α, NO, and ROS, and suppressed the expression of iNOS and COX-2. Mol Med Rep. 2021 Oct;24(4):698
HeLa-mitoKeima-PARKIN cells 25 and 50 μM 24 hours To assess the ability of G-Re to induce mitophagy, results showed that G-Re significantly increased the population of mitophagy-positive cells. J Ginseng Res. 2025 Jan;49(1):92-102

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Wild-type mice and prodynorphin knockout mice Intraperitoneal injection 20 mg/kg Twice daily for 7 consecutive days (5 days before and 1 day after MA injection) Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor. J Neuroinflammation. 2018 Feb 21;15(1):52
Zebrafish Zebrafish scale model Water solution 50 μM Daily water replacement for 35 days To evaluate the effect of ginsenoside Re on zebrafish scale mineralization, results showed significant increase in calcium deposition at 50 μM. Molecules. 2016 Dec 29;22(1):42
C57BL/6 mice Acute myocardial infarction model Intragastric administration 19.5 mg/kg/d, 39 mg/kg/d Once daily for 4 weeks To investigate the effect of Ginsenoside Re on myocardial fibrosis in mice with acute myocardial infarction. Results showed that Ginsenoside Re could improve cardiac function, inhibit collagen deposition and cardiac fibroblast migration, promote miR-489 transcription, and reduce myd88 expression and NF-κB p65 phosphorylation. J Ginseng Res. 2023 Mar;47(2):218-227
Caenorhabditis elegans Wild-type N2 Caenorhabditis elegans and specific mutants Oral 10, 20, and 50 μM Continuous administration To evaluate the effects of G-Re on lifespan and health metrics, results showed that G-Re extended lifespan and improved health metrics such as movement speed and stress resistance. J Ginseng Res. 2025 Jan;49(1):92-102
Balb/c mice Cyclophosphamide-induced myelosuppression model Intraperitoneal injection 5 and 10 mg/kg Once a day for 7 consecutive days To investigate the effects of Ginsenoside Re on cyclophosphamide-induced myelosuppression, results showed that Re improved peripheral blood cell counts, bone marrow nucleated cell counts, thymus index, and spleen index, and regulated cytokine levels and cell cycle. J Ginseng Res. 2019 Oct;43(4):618-624
Zebrafish Zebrafish scale model Water administration 5 μM Once daily for 35 days To evaluate the inhibitory effect of Ginsenoside Re on osteoclast differentiation in zebrafish scales, results showed that Ginsenoside Re significantly reduced TRAP-positive signals and the expression of osteoclast marker genes. Mol Cells. 2016 Dec;39(12):855-861

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.06mL

0.21mL

0.11mL

5.28mL

1.06mL

0.53mL

10.56mL

2.11mL

1.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Wang L, Yuan D, et al. Ginsenoside Re Promotes Nerve Regeneration by Facilitating the Proliferation, Differentiation and Migration of Schwann Cells via the ERK- and JNK-Dependent Pathway in Rat Model of Sciatic Nerve Crush Injury. Cell Mol Neurobiol. 2015 Aug;35(6):827-40.

[2]Sukrittanon S, Watanapa WB, Ruamyod K. Ginsenoside Re enhances small-conductance Ca(2+)-activated K(+) current in human coronary artery endothelial cells. Life Sci. 2014 Oct 12;115(1-2):15-21.

[3]Cao G, Su P, Zhang S, et al. Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells. Eur J Pharmacol. 2016;793:101-108

[4]Wang QW, Yu XF, Xu HL, Zhao XZ, Sui DY. Ginsenoside Re Improves Isoproterenol-Induced Myocardial Fibrosis and Heart Failure in Rats. Evid Based Complement Alternat Med. 2019;2019:3714508. Published 2019 Jan 1

[5]Dang DK, Shin EJ, Kim DJ, et al. Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor. J Neuroinflammation. 2018;15(1):52. Published 2018 Feb 21

[6]Lee GH, Lee WJ, Hur J, Kim E, Lee HG, Seo HG. Ginsenoside Re Mitigates 6-Hydroxydopamine-Induced Oxidative Stress through Upregulation of GPX4. Molecules. 2020;25(1):188. Published 2020 Jan 2

[7]Gao Y, Gao CY, Zhu P, et al. Ginsenoside Re inhibits vascular neointimal hyperplasia in balloon-injured carotid arteries through activating the eNOS/NO/cGMP pathway in rats. Biomed Pharmacother. 2018;106:1091-1097

 

Historical Records

Categories